Hims & Hers Health Inc. is making headlines on the New York Stock Exchange as its stock continues to soar, reflecting a significant buzz in the market. The company has seen its stock nearly double since hitting a low in late February, now trading at $25.52, up 4.5% on the day. The excitement stems from an upcoming FDA meeting scheduled for July, where several peptides might be approved for production by compounding pharmacies. This regulatory shift could open up lucrative new markets for Hims & Hers, easing the pressure on their GLP-1 prospects.
Strong Market Performance
The stock is on track for its fourth consecutive gain, having surged by 13.7% just yesterday. Since reaching a two-year low of $13.74 on February 24, shares have rebounded impressively, surpassing their 80-day moving average for the first time since October. Nevertheless, the stock remains down 21% for the year, indicating that while recent developments are positive, the journey has not been without its challenges.
Short Selling and Market Dynamics
Hims & Hers is currently one of the most shorted stocks on the market, with 34.5% of its total float sold short. This high short interest could create a volatile environment, particularly if analysts begin to adjust their ratings. Currently, 12 out of 15 brokerages maintain “hold” ratings, suggesting a cautious optimism among financial experts.
Options Activity Highlights
A significant uptick in options trading has been noted, particularly on platforms like the International Securities Exchange and Cboe Options Exchange. The current 10-day call/put volume ratio stands at 6.76, placing it in the top percentile for the year. This suggests a strong interest in bullish positions, although some traders may also be hedging their bets against potential declines.
Increased Trading Volume
In the early hours of trading, an impressive 131,000 call options exchanged hands, six times the average daily volume and seven times the number of puts traded. The most popular options include the weekly 4/24 28-strike call and the longer-dated May 30 calls. This surge in activity reflects growing confidence among investors regarding the company’s future prospects.
Volatility and Trading Strategy
For those involved in trading Hims & Hers, the stock’s Schaeffer’s Volatility Scorecard (SVS) is an encouraging sign, scoring 87 out of 100. This indicates that the stock has consistently experienced higher volatility than what options pricing might suggest, presenting opportunities for savvy traders to capitalize on market movements.
Regulatory Changes on the Horizon
In addition to developments at Hims & Hers, the SEC is making waves by moving to eliminate the $25,000 minimum requirement for day trading accounts. This change could unlock opportunities for a broader range of traders, potentially introducing a new wave of market participants eager to engage with dynamic stocks like Hims & Hers.
Conclusion
Hims & Hers is navigating a promising landscape, bolstered by regulatory changes and a significant rebound in stock performance. As the company prepares for the FDA meeting and continues to attract attention in the options market, investors will be keenly watching how these developments unfold. The combination of increased trading activity and the potential for new market access positions Hims & Hers as a company to watch in the biotech sector.
- Key Takeaways:
- Hims & Hers stock has nearly doubled since late February.
- The upcoming FDA meeting on peptide regulations could significantly benefit the company.
- High short interest may lead to increased volatility in the stock.
- Options trading activity is at an all-time high, reflecting investor confidence.
- The SEC’s removal of trading barriers could attract new traders to the market.
Read more → www.schaeffersresearch.com